Why the study?
Can HMB45 immunoreactivity on transbronchial biopsy reliably diagnose pulmonary lymphangiomyomatosis?
Population
75 lung specimens with various lesions and 20 normal lung specimens
Comparison
Immunohistochemical staining for… vs Other lung lesions and normal lung tissue
Design
Cross-sectional
Authors
Loading...
HMB45 may support PLAM diagnosis on transbronchial biopsy; leaves open prospective validation before routine adoption.
Can HMB45 immunoreactivity on transbronchial biopsy reliably diagnose pulmonary lymphangiomyomatosis?
HMB45 immunoreactivity is a specific marker for pulmonary lymphangiomyomatosis, allowing for diagnosis from transbronchial biopsy specimens.
Bonetti et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: